Commitments and Contingencies - Additional Information (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
May 07, 2019 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
|
| Commitments And Contingencies [Line Items] | ||||||
| Common stock fair value | $ 8,000 | $ 8,000 | $ 6,000 | |||
| Common stock, shares issued | 80,070,048 | 80,070,048 | 71,419,025 | |||
| Expenses incurred related to purchase commitments | $ 500,000 | $ 100,000 | $ 500,000 | $ 200,000 | ||
| Minimum purchase obligation | $ 1,100,000 | $ 1,100,000 | ||||
| Common Stock | ||||||
| Commitments And Contingencies [Line Items] | ||||||
| Warrants issued to purchase shares | 3,859,000 | 3,859,000 | ||||
| VOQUEZNA TRIPLE PAK | ||||||
| Commitments And Contingencies [Line Items] | ||||||
| Percentage of total revenue represented by product | 1.00% | |||||
| Takeda License | ||||||
| Commitments And Contingencies [Line Items] | ||||||
| Royalty expense | $ 7,400,000 | $ 4,000,000 | $ 13,300,000 | $ 6,800,000 | ||
| Royalty expense included in accrued expenses | $ 7,400,000 | $ 7,400,000 | ||||
| Takeda License | Takeda | ||||||
| Commitments And Contingencies [Line Items] | ||||||
| License agreement description | On May 7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe, or the Takeda License. The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months’ written notice. The Company and Takeda may terminate the Takeda License in the case of the other party’s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents. | |||||
| Agreement expiration term from date of first commercial sale | 15 years | |||||
| Cash consideration paid for license | $ 25,000,000 | |||||
| Common stock fair value | $ 5,900,000 | |||||
| Common stock, shares issued | 1,084,000 | |||||
| Warrants exercise price | $ 0.00004613 | |||||
| Initial fair value of warrants | $ 47,900,000 | |||||
| Additional warrant issued | 0 | |||||
| Maximum amount payable in sales milestones upon achievement of specified levels of product sales | $ 250,000,000 | |||||
| Warrants expiration date | May 07, 2029 | |||||
| Takeda License | Takeda | Common Stock | ||||||
| Commitments And Contingencies [Line Items] | ||||||
| Warrants issued to purchase shares | 7,588,000 | |||||